Actively Recruiting
Evaluating Safety and Preliminary Efficacy of HS-IT101 Injection for Advanced Non-Small Cell Lung Cancer Treatment
Led by Hangzhou Huasai Biomedicine Co., Ltd. · Updated on 2026-10-14
24
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of HS-IT101, an autologous tumor-infiltrating lymphocyte TIL cell therapy, in patients with advanced non-small cell lung cancer NSCLC who have not responded to or cannot tolerate standard treatments. This phase Ib, open-label, single-arm study aims to assess the safety, tolerability, and preliminary efficacy of HS-IT101 in this patient group. The study is sponsored by Hangzhou Huasai Biomedicine Co., Ltd. and focuses on a treatment approach involving lymphodepleting preconditioning followed by TIL cell therapy. Participants receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine, each given once daily via intravenous infusion for three consecutive days. Following this, they are treated with HS-IT101 administered by intravenous infusion over 30 to 60 minutes. After the TIL infusion, patients receive interleukin-2 IL-2 therapy via subcutaneous or intravenous injection up to three times, with dosing adjusted based on tolerance. This treatment regimen is designed to support the effectiveness of the TIL therapy against the cancer. Throughout the study, participants undergo regular assessments for safety and treatment effects over two years. These include monitoring organ and bone marrow function, heart function via echocardiography, oxygen saturation, and adverse events using established criteria. Researchers also evaluate the pharmacokinetic profile of HS-IT101. Patients must comply with scheduled visits and procedures, and the study measures both safety and preliminary efficacy outcomes to understand how well the therapy works and is tolerated over time.
CONDITIONS
Brief Title
A Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer(FASTIL-Lung02)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here